Kymera Therapeutics presented new preclinical data for KT-579, an oral IRF5 degrader, showing it effectively modulates multiple inflammatory pathways in inflammatory bowel disease (IBD) models. KT-579 demonstrated comparable or superior activity to existing therapies by reducing key inflammatory cytokines and improving disease markers. The drug is currently in a Phase 1 trial with healthy volunteers, focusing on safety and IRF5 degradation, with results expected in the second half of 2026. This novel oral treatment could offer a new option for patients with complex autoimmune diseases like IBD.
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
Corbin Advisors' Q2 2026 survey shows industrial investor sentiment at its highest in five years, with 84% of participants bullish or neutral-to-bullish due to strong order momentum and demand from data centers and AI sectors. Expectations for Q2 rev...
VNET Group is recommended as a buy due to its large, committed pipeline of data center capacity that is expected to boost earnings growth. The company benefits from secured power resources and established campuses, giving it a competitive edge in sup...
Bitcoin and XRP prices remained steady near critical support levels as investors awaited discussions on the CLARITY Act, a significant crypto regulation bill. The broader crypto market dipped 1.35%, with Bitcoin around $64,000 and XRP just above $1.1...
Vista Energy aims to grow production to over 200,000 barrels of oil equivalent per day by 2028 through organic growth and strategic acquisitions. The company focuses on low operating costs and self-funded expansion, achieving an EBITDA run rate above...
